Amgen 2000 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2000 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 47

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47

17
“Amgen is committed to turning the unprecedented possibil-
ities of science into the realities of therapeutic cancer
treatment. It’s a commitment supported by Amgen’s substan-
tial resources in areas ranging from exploratory research and
cancer biology to clinical oncology and development. Fulfilling
Amgen’s aspiration to be the best human therapeutics
company demands more than the success we have had in
cancer supportive care. It demands that we produce solutions
that make us the therapeutic partner of choice in cancer treat-
ment. This is why I recently left academia to join Amgen.
Amgen uses a broad spectrum of approaches to develop
cancer therapeutics, including small molecule, antibody, and
protein approaches. Supporting this work, the company has
made major investments in genomics, proteomics, gene
expression analysis, small molecule science, antibody tech-
nologies, and kinase biology. Our researchers work closely
with Amgen’s preclinical and clinical oncology groups to expe-
dite the development of novel cancer therapies. All researchers
likewise support the in-licensing of exciting new cancer thera-
peutic candidates.
Before joining Amgen, I worked for 11 years as a tenured
cancer researcher at the University of Texas M.D. Anderson
Cancer Center. My work there focused on host/tumor interac-
tions mediating tumor cell survival, growth, and angiogenesis
during the spread of cancer cells to distant organs in the body.
The opportunity to continue my translational cancer
research at a science-based company with a clear commit-
ment to targeted cancer therapeutics was, simply, too great to
pass up. As a PhD molecular and cellular cancer biologist who
has worked in all aspects of cancer research (from laboratory
bench to bedside), I have sworn to helping patients first.
Working at Amgen, I believe I can help more patients than in
any other way.”
Bob Radinsky, PhD
Preclinical Cancer Researcher
Amgen
Colorized micrograph of colon cancer,
prepared following surgical resection.